References
- KassMAHeuerDKHigginbothamEJThe Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucomaArch Ophthalmol200212070171312049574
- HeijlALeskeMCBengtssonBThe Early Manifest Glucoma Trial GroupReduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma TrialArch Ophthalmol20021201268127912365904
- DaileyRABrubakerRFBourneWMThe effects of timolol maleate and acetazolamide on the rate of aqueous formation in normal human subjectsAm J Ophthalmol1982932322377039328
- CostagliolaCOmoRRomanoRPharmacotherapy of intraocular pressure – part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamidesExpert Opin Pharmacother2009102859287019929706
- AlmAProstaglandin derivatives as ocular hypotensive agentsProg Retin Eye Res1998172913129695796
- SchachtschabelULindseyJDWeinrebRNThe mechanism of action of prostaglandins on uveoscleral outflowCurr Opin Ophthalmol20001111211510848216
- TsaiJCMcClureCARamosSECompliance barriers in glaucoma: a systematic classificationJ Glaucoma20031239339814520147
- RobinALCovertDDoes adjunctive glaucoma therapy affect adherence to the initial primary therapy?Ophthalmology200511286386815878067
- RobinALNovackGDCovertDWAdherence in glaucoma: objective measurements of once daily and adjunctive medication useAm J Ophthalmology2007144533540
- FechtnerRDRealiniTFixed combinations of topical glaucoma medicationsCurr Opin Ophthalmol20041513213515021225
- KabackMScoperSVArzenoGIntraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%Am Acad Ophthalmol200811517281734
- ManniGDenisPChewPThe safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertensionJ Glaucoma20091829330019365194
- MundorfTKRauchmanSHWilliamsRDMotivolRA patient preference comparison of Azarga™ (brinzolamide/timolol fixed combination) vs Cosopt® (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertensionClin Ophthalmol2008262362819668763
- DohertyMDFraserSGPhelanPSBrinzolamide-timolol suspension: acceptability and side effect profileClin Ophthalmol2011541942321499567
- RossiGCMPasinettiGMSandoloFFrom dorzolamide 2%/timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: a 6-month, multicenter, open-label tolerability switch studyExpert Opin Pharmacother2011122425243121679090
- SilverLHOcular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicentre comfort studies. Brinzolamide Comfort Study GroupSurv Ophthalmol200044Suppl 2S141S14510665516
- StewartWCDayDGStewartJAShort-term ocular tolerability of dorzolamide 2% and brinzolamide 1% vs placebo in primary open angle glaucoma and ocular hypertension subjectsEye20041890591015002017
- MichaudJEFrirenBInternational Brinzolamide Adjunctive Study GroupComparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open angle glaucoma or ocular hypertensionAm J Ophthalmol200113223524311476685
- JampelHDSchwartzGFRobinALPatient preferences for eye drop characteristics: a willingness-to-pay analysisArch Ophthalmol200312154054612695251